首頁 > 市場調查報告書 > 製藥

疫苗

市場調查報告書

商品編碼

1736513

2026-2032 年黃熱病疫苗市場（按治療類型、最終用戶和地區分類）

Yellow Fever Vaccine Market By Treatment Type (Pain Management Drugs, Oral Rehydration), By End-User (Hospitals, Point-of-Care Centers, Diagnostic Centers), & Region For 2026-2032

出版日期: 2025年05月05日 | 出版商:

Verified Market Research | 英文 | 商品交期: 2-3個工作天內

價格

簡介目錄

黃熱病疫苗市場評估-2026-2032

國際旅行的增加，進入流行國家需要遵守疫苗接種規定，以及疫苗技術的進步提高了可及性和有效性，這些都推動了黃熱病疫苗市場的發展。根據 Verified Market Research 分析師的預測，黃熱病疫苗市場規模預計將在 2023 年下降約 1.4487 億美元，並在預測期內達到 2.1864 億美元的估值。

全球健康計劃和對黃熱病威脅的認知不斷提高正在推動需求，特別是隨著流行地區的擴大和越來越多的旅行者尋求接種疫苗以確保人身安全，這將推動市場在 2026 年至 2032 年期間以 5.28% 的複合年成長率成長。

黃熱病疫苗市場定義/概述

黃熱病疫苗是一種減毒活疫苗，用於預防黃熱病。黃熱病是一種主要在非洲和南美洲流行的危險蚊媒疾病。單次皮下注射通常可提供終身保護，對於居住在疫區或前往疫區旅行的人來說至關重要。進入某些國家也需要接種該疫苗，這反映了其在國際旅行衛生法規中的重要性。除了個人預防外，黃熱病疫苗對於疫情控制也至關重要，並為全球公共衛生工作（包括建議高風險族群進行常規疫苗接種）做出了巨大貢獻。

黃熱病疫苗接種的主要促進因素是什麼？

全球旅行的增加，尤其是前往黃熱病流行國家的旅行，正在推動黃熱病疫苗的需求。根據世界旅遊組織 (UNWTO) 的數據，2019 年國際觀光人數達 15 億，其中相當一部分前往黃熱病流行地區。根據美國疾病管制與預防中心 (CDC) 的數據，2019 年有近 900 萬美國前往了建議或要求接種黃熱病疫苗的國家。

氣候變遷和都市化導致黃熱病風險地區擴大，疫苗接種需求也隨之增加。世界衛生組織（WHO）數據顯示，2017年至2018年期間，美洲七個國家報告了確診的黃熱病病例，其中包括先前被認為無風險的地區。 2017年7月至2018年6月期間，巴西報告了1,376例確診黃熱病病例，凸顯了黃熱病威脅日益加劇以及疫苗接種的必要性。

此外，各國政府和國際衛生組織正在實施大規模疫苗接種計劃，以預防黃熱病疫情。據世界衛生組織和聯合國兒童基金會稱，在2016-2017年安哥拉和剛果民主共和國爆發黃熱病疫情期間，緊急宣傳活動為約3,000萬人接種了疫苗。此外，世界衛生組織的「終結黃熱病」（EYE）舉措旨在到2026年為10億人接種疫苗，這將增加對黃熱病疫苗的需求。

哪些挑戰阻礙了黃熱病疫苗市場的成長？

黃熱病疫苗的潛在副作用是市場成長的主要障礙。常見的副作用包括頭痛、肌肉疼痛和疲勞，這些副作用會阻礙人們接種疫苗。對這些副作用的擔憂導致疫苗需求下降，尤其是在那些對疫苗接種持謹慎態度的人群中。這種猶豫降低了旨在控制黃熱病發生的疫苗接種的整體有效性。

此外，基礎設施瓶頸也對市場產生了重大影響。疫苗必須透過先進的低溫運輸物流配送，才能在運輸和儲存過程中保持其有效性。在許多黃熱病流行地區，有限的醫療設施和物流瓶頸阻礙了及時的疫苗接種工作。這些限制因素限制了弱勢族群獲得疫苗的機會，從而阻礙了預防黃熱病傳播的努力，最終影響了市場成長。

The rising international travel, which requires vaccination compliance for admission into endemic countries, and technological developments in vaccines that improve accessibility and efficacy are driving the Yellow Fever Vaccine Market. According to the analyst from Verified Market Research, the Yellow Fever Vaccine Market is estimated to reach a valuation of USD 218.64 Million over the forecast subjugating around USD 144.87 Million in 2023.

The global health initiatives and increased knowledge of yellow fever threats are driving up demand, especially as endemic zones grow and more travelers seek inoculation for personal safety. It enables the market to grow at a CAGR of 5.28% from 2026 to 2032.

Yellow Fever Vaccine Market: Definition/ Overview

The yellow fever vaccine is a live, attenuated virus vaccine used to prevent yellow fever, a dangerous disease spread mostly by mosquitos in Africa and South America. When given as a single subcutaneous dose, it often gives lifelong protection, making it critical for anyone living in or going to endemic areas. The vaccine is also necessary for entry into certain countries, demonstrating its importance in international travel health rules. The yellow fever vaccine has applications beyond individual protection; it is critical in outbreak control and is recommended for routine immunization in at-risk populations, considerably contributing to worldwide public health initiatives.

What are the Key Drivers that Foster the Adoption of Yellow Fever Vaccines?

The increase in worldwide travel, particularly to yellow fever-endemic countries, is driving up demand for yellow fever vaccines. According to the World Tourism Organization (UNWTO), international tourist arrivals totaled 1.5 billion in 2019, with a sizable proportion of these visitors traveling to areas where yellow fever is prevalent. According to the Centers for Disease Control and Prevention (CDC), nearly 9 million Americans visited countries where yellow fever vaccination is recommended or necessary in 2019.

Climate change and urbanization are contributing to the spread of yellow fever risk areas, increasing the demand for vaccination. According to the World Health Organization (WHO), seven nations in the Americas reported verified yellow fever cases between 2017 and 2018, including areas that were previously considered risk-free. Between July 2017 and June 2018, 1,376 confirmed cases of yellow fever were reported in Brazil, underscoring the growing threat and need for vaccinations.

Furthermore, governments and international health organizations are putting in place large-scale vaccination programs to prevent yellow fever epidemics. According to WHO and UNICEF, almost 30 million people were vaccinated in emergency campaigns during the yellow fever outbreaks in Angola and the Democratic Republic of the Congo in 2016-2017. Also, the WHO's Eliminate Yellow Fever Epidemics (EYE) initiative seeks to vaccinate 1 billion people by 2026, increasing demand for yellow fever vaccines.

What are the Challenges Hindering the Growth of the Yellow Fever Vaccine Market?

The potential negative effects of the yellow fever vaccine are a substantial barrier to market growth. Common adverse responses include headaches, muscle soreness, and exhaustion, which discourage people from getting vaccinated. Concerns about these side effects contribute to decreased demand, particularly among people who are already wary of immunizations. This hesitation reduces the overall effectiveness of vaccination initiatives aimed at limiting yellow fever outbreaks.

Furthermore, infrastructure bottlenecks have a big impact on the market. To preserve efficacy during shipping and storage, vaccinations must be distributed via sophisticated cold-chain logistics. In many endemic areas, limited healthcare facilities and logistical obstacles prevent timely immunization efforts. These constraints restrict vulnerable groups' access to vaccines, ultimately hampering attempts to prevent the spread of yellow fever and affecting market growth.

Category-Wise Acumens

What Factors Contribute to the Market Leadership of Oral Rehydration Treatment?

According to VMR analysis, the oral rehydration segment is estimated to hold the largest market share during the forecast period due to the high prevalence of dehydration associated with yellow fever, which demands rapid rehydration therapy as the first line of treatment. Oral rehydration treatments are effective in replacing lost fluids and electrolytes, making them necessary for patient recovery. This acute requirement for hydration promotes the demand for oral rehydration solutions in the market.

Health agencies such as the World Health Organization (WHO) and UNICEF strongly support oral rehydration as a critical treatment for yellow fever-induced dehydration, which is a further major concern. Their campaign not only promotes awareness but also inspires healthcare providers to prioritize oral rehydration products, resulting in increased market growth and acceptance by patients.

Furthermore, the growing availability and diversity of oral rehydration products help to maintain the segment's dominance. Formulation innovations like flavored liquids and effervescent tablets improve patient compliance and happiness. As these medications become more widely available through multiple distribution channels, they strengthen their position as the primary treatment for yellow fever-related dehydration.

What are the Key Driving Forces for the Yellow Fever Vaccines in Hospitals?

The hospital segment is estimated to dominate the Yellow Fever Vaccine Market during the forecast period due to the increasing dominance is increased vaccination awareness among visitors and local populations in endemic areas. Hospitals are key healthcare providers where people get immunizations, especially before going to locations where yellow fever is common. This increased knowledge results in an increase in hospital visits for immunizations, cementing their segment position.

The provision of comprehensive healthcare services in hospitals is a further significant factor driving the segment. These facilities not only provide vaccines but also offer pre-vaccination consultations and post-vaccination care, boosting patient trust and encouraging more people to get immunized. This integrated approach leads to higher immunization rates than in other contexts.

Furthermore, government initiatives and health programs focused on limiting yellow fever outbreaks prioritize hospital vaccination campaigns. Collaboration between hospitals and public health agencies ensures that vaccines are easily available, particularly during outbreaks or high travel seasons, bolstering hospitals' market position.

Country/Region-wise Acumens

What Drivers Contribute to the Sustained Dominance of North America in this Market?

According to VMR analyst, North America is estimated to dominate the Yellow Fever Vaccine Market during the forecast period. North America, particularly the United States, has a large number of international visitors to yellow fever endemic areas. According to the National Travel and Tourism Office of the United States Department of Commerce, 93.0 million Americans left the country for overseas travel in 2018 alone. According to the Centers for Disease Control and Prevention (CDC), nearly 9 million Americans visited countries where yellow fever vaccination is recommended or necessary in 2019. The increasing number of visitors to high-risk areas fuels the demand for yellow fever vaccines in the North American market.

Furthermore, North America, particularly the United States and Canada, has a well-developed healthcare and vaccination infrastructure. The CDC's Advisory Committee on Immunization Practices (ACIP) advises yellow fever immunization for visitors to endemic countries. In 2019, the CDC estimated that there were over 4,500 yellow fever vaccination clinics in the United States, ensuring extensive availability of the vaccine. This broad network of vaccination centers contributes to the region's dominant position in the Yellow Fever Vaccine Market.

What are the Factors Leading to Substantial Growth of the Market in Europe?

Europe region is estimated to exhibit substantial growth within the market during the forecast period. International travel in Europe has increased significantly, particularly to regions where yellow fever is widespread. According to the European Travel Commission, European outward travel grew by 7% in 2019, totaling 1.1 billion trips. The European Centre for Disease Prevention and Control (ECDC) reported 13 travel-associated yellow fever cases among European visitors between 2012 and 2018, emphasizing the importance of vaccination for European tourists visiting endemic locations. This expanding trend in foreign travel is a significant driver of the Yellow Fever Vaccine Market in Europe.

Furthermore, strong immunization and public health initiatives have been put in place by European nations to safeguard tourists. According to the World Health Organization's (WHO) European Region, there were over 7,000 authorized yellow fever vaccination facilities throughout Europe in 2019. According to France's National Public Health Agency, the number of yellow fever vaccination doses administered climbed from 169,000 in 2015 to 194,000 in 2019. The broad availability and use of yellow fever vaccinations help to drive market expansion in Europe.

Competitive Landscape

The competitive landscape of the Yellow Fever Vaccine Market is characterized by a dynamic interaction of innovation, regulatory compliance, and strategic alliances. As the demand for yellow fever immunization rises due to increased international travel and health advisories, stakeholders are working on improving vaccine efficacy and accessibility through advanced R&D projects.

Some of the prominent players operating in the Yellow Fever Vaccine Market include:

Takeda Pharmaceutical Company Ltd, Merck & Co, Inc., GlaxoSmithKline PLC, Biological E Limited, Panacea Biotec, iBio, Inc., FSUE Chumakov, Institut Pasteur de Dakar, Bio Manguinhos, and Sanofi Pasteur SA.

Latest Developments

In April 2021, Sanofi Pasteur announced that YF-VAX is now available for purchase in the United States. YF-VAX can now be ordered from the manufacturer by providers who have a current Yellow Fever Vaccination Stamp from their state or territory health department.

1 INTRODUCTION OF GLOBAL YELLOW FEVER VACCINE MARKET

1.1 Overview of the Market
1.2 Scope of Report
1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

3.1 Data Mining
3.2 Validation
3.3 Primary Interviews
3.4 List of Data Sources

4 GLOBAL YELLOW FEVER VACCINE MARKET OUTLOOK

4.1 Overview
4.2 Market Dynamics
- 4.2.1 Drivers
- 4.2.2 Restraints
- 4.2.3 Opportunities
4.3 Porters Five Force Model
4.4 Value Chain Analysis

5 GLOBAL YELLOW FEVER VACCINE MARKET, BY TREATMENT TYPE

5.1 Overview
5.2 Pain Management Drugs
5.3 Oral Rehydration

6 GLOBAL YELLOW FEVER VACCINE MARKET, BY END USER

6.1 Overview
6.2 Hospitals
6.3 Diagnostic Centers
6.4 Point of Care Centers
6.5 Others

7 GLOBAL YELLOW FEVER VACCINE MARKET, BY GEOGRAPHY

7.1 Overview
7.2 North America
- 7.2.1 U.S.
- 7.2.2 Canada
- 7.2.3 Mexico
7.3 Europe
- 7.3.1 Germany
- 7.3.2 U.K.
- 7.3.3 France
- 7.3.4 Rest of Europe
7.4 Asia Pacific
- 7.4.1 China
- 7.4.2 Japan
- 7.4.3 India
- 7.4.4 Rest of Asia Pacific
7.5 Rest of the World
- 7.5.1 Latin America
- 7.5.2 Middle East & Africa

8 GLOBAL YELLOW FEVER VACCINE MARKET COMPETITIVE LANDSCAPE

8.1 Overview
8.2 Company Market Ranking
8.3 Key Development Strategies

9 COMPANY PROFILES

9.1 Takeda Pharmaceutical Company Ltd
- 9.1.1 Overview
- 9.1.2 Financial Performance
- 9.1.3 Product Outlook
- 9.1.4 Key Developments
9.2 Merck & Co Inc
- 9.2.1 Overview
- 9.2.2 Financial Performance
- 9.2.3 Product Outlook
- 9.2.4 Key Developments
9.3 GlaxoSmithKline PLC
- 9.3.1 Overview
- 9.3.2 Financial Performance
- 9.3.3 Product Outlook
- 9.3.4 Key Developments
9.4 Biological E Limited
- 9.4.1 Overview
- 9.4.2 Financial Performance
- 9.4.3 Product Outlook
- 9.4.4 Key Developments
9.5 Panacea Biotec
- 9.5.1 Overview
- 9.5.2 Financial Performance
- 9.5.3 Product Outlook
- 9.5.4 Key Developments
9.6 iBio Inc
- 9.6.1 Overview
- 9.6.2 Financial Performance
- 9.6.3 Product Outlook
- 9.6.4 Key Developments
9.7 FSUE Chumakov
- 9.7.1 Overview
- 9.7.2 Financial Performance
- 9.7.3 Product Outlook
- 9.7.4 Key Developments
9.8 Institut Pasteur de Dakar
- 9.8.1 Overview
- 9.8.2 Financial Performance
- 9.8.3 Product Outlook
- 9.8.4 Key Developments
9.9 Bio Manguinhos
- 9.9.1 Overview
- 9.9.2 Financial Performance
- 9.9.3 Product Outlook
- 9.9.4 Key Developments
9.10 Sanofi Pasteur SA
- 9.10.1 Overview
- 9.10.2 Financial Performance
- 9.10.3 Product Outlook
- 9.10.4 Key Developments